Catalyst Brief

← Calendar

ReadoutIn window

Bristol-Myers Squibb — Deucravacitinib

Phase 3 primary completion: Efficacy and safety of Deucravacitinib in adults with active Sjögren's Syndrome.

Date
Nov 2026
Type
Readout
Ticker
BMY
Indication
Sjögren's Syndrome

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Bristol-Myers Squibb

  1. Mar2027